久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

瑞士Molecular Partners  


Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.

We address real medical needs and develop cutting-edge medicine based on innovative DARPin products.

The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, an inhibitor of VEGF, which has completed two separate Phase I/IIa clinical trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), the most common causes for vision loss. Further products are in research and preclinical development. We balance our internal drug development efforts with strategic alliances with renowned pharmaceutical companies.

Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.